| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $11.6M | — | -15.1% |
| SG&A Expense | $5.3M | — | +19.5% |
| Operating Income | -$16.9M | — | +6.7% |
| Net Income | -$14.5M | — | +9.6% |
| EPS (Basic) | -$0.39 | — | +37.1% |
| EPS (Diluted) | -$0.39 | — | +37.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $20.2M | -73.3% | -10.3% |
| Short-term Investments | $226.2M | +20.8% | +34.4% |
| Current Assets | $253.0M | -5.6% | +31.7% |
| Total Assets | $261.3M | -5.5% | +31.8% |
| Current Liabilities | $6.7M | -31.7% | -25.6% |
| Total Liabilities | $11.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$16.3M | — | -12.9% |
| Capital Expenditures | $312K | — | +563.8% |
| Investing Cash Flow | -$39.3M | — | -363.5% |
| Financing Cash Flow | $129K | — | +437.5% |
| Free Cash Flow | -$16.6M | — | -14.7% |
| -16.2% |
| Stockholders' Equity | $250.0M | -4.2% | +35.3% |